HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial:: an extended virology study

被引:25
|
作者
Aboulker, JP [1 ]
Babiker, AG [1 ]
Brun-Vézinet, F [1 ]
Darbyshire, JH [1 ]
Flandre, P [1 ]
Gazzard, B [1 ]
Nunn, AJ [1 ]
Goodall, R [1 ]
Aber, V [1 ]
Bragman, K [1 ]
Breckenridge, AM [1 ]
Carbon, C [1 ]
Charreau, I [1 ]
Chene, G [1 ]
Collis, P [1 ]
Cooper, D [1 ]
Dormont, J [1 ]
Fiddian, P [1 ]
Flepp, M [1 ]
Goebel, FD [1 ]
Hooker, M [1 ]
Lange, J [1 ]
Lüthy, R [1 ]
Peto, TEA [1 ]
Reiss, P [1 ]
Seligmann, M [1 ]
Stone, AB [1 ]
Thomis, J [1 ]
Vella, S [1 ]
Walckenaer, G [1 ]
Warrell, D [1 ]
Weller, IVD [1 ]
Wilber, R [1 ]
Yeni, P [1 ]
Yeo, J [1 ]
Withnall, R [1 ]
Goudsmit, J [1 ]
Huraux, JM [1 ]
van der Noorda, J [1 ]
Weiss, R [1 ]
Boucher, C [1 ]
Schuurman, R [1 ]
Descamps, D [1 ]
Jeffries, D [1 ]
Tedder, R [1 ]
Weber, J [1 ]
Krzyanowski, C [1 ]
Weverling, G [1 ]
机构
[1] UCL, Sch Med, Mortimer Market Ctr, MRC,Clin Trials Unit, London WC1E 6AU, England
关键词
antiviral therapy; progression; HIV-1; RNA; viral load;
D O I
10.1097/00002030-199901140-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To assess changes in HIV RNA and their relationship to disease progression. Design and setting: Delta was a randomized double-blind trial comparing zidovudine (ZDV) monotherapy with ZDV plus didanosine (ddl) or ZDV plus zalcitabine (ddC). Participants had AIDS (with CD4 cell counts above 50 x 10(6)/l), AIDS-related complex, or were asymptomatic with CD4 cell counts below 350 x 10(6)/l. The trial included both ZDV-naive and ZDV-experienced participants. Participants: A total of 1280 participants in the Delta trial whose serum samples had been stored at -70 degrees C and who had a minimum of one sample taken before the start of treatment and at least one later sample. Methods: HIV-1 RNA quantification was performed using the nucleic acid sequence-based amplification HIV-1 RNA quantitative assay with a cut-off of 800 copies/ml. Results: Reductions in HIV RNA by treatment group were consistent with the clinical results; in ZDV-naive participants the maximum median fall occurred at 4 weeks for all three groups (ZDV, 0.54 log(10) copies/ml; ZDV-ddl, 1.38 log(10) copies/ml; ZDV-ddC, 1.31 log(10), copies/ml). On average the reductions were smaller in ZDV-experienced participants but the difference between the monotherapy and combination arms was very similar in ZDV-naive and experienced participants. Baseline HIV RNA levels, adjusted for CD4 cell counts were highly predictive of time to virological response (HIV RNA < 800 copies/ml); HIV RNA nadirs achieved were predictive of survival. Viral load rebound following response was independent of treatment group and previous ZDV therapy. Conclusions: Virological changes in response to treatment are of Value in assessing prognosis and the activity of new therapies; in particular, there is a strong association between the minimum HIV RNA achieved in the first 16 weeks and subsequent clinical response. CD4 cell counts are independently predictive of response. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:57 / 65
页数:9
相关论文
共 50 条
  • [41] RNA interference approaches for treatment of HIV-1 infection
    Maggie L Bobbin
    John C Burnett
    John J Rossi
    Genome Medicine, 7
  • [42] RNA interference approaches for treatment of HIV-1 infection
    Bobbin, Maggie L.
    Burnett, John C.
    Rossi, John J.
    GENOME MEDICINE, 2015, 7
  • [43] Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment
    Thiébaut, R
    Morlat, P
    Jacqmin-Gadda, H
    Neau, D
    Mercié, P
    Dabis, F
    Chêne, G
    AIDS, 2000, 14 (08) : 971 - 978
  • [44] Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants
    Bednasz, Cindy J.
    Venuto, Charles S.
    Ma, Qing
    Daar, Eric S.
    Sax, Paul E.
    Fischl, Margaret A.
    Collier, Ann C.
    Smith, Kimberly Y.
    Tierney, Camlin
    Yang, Yang
    Wilding, Gregory E.
    Morse, Gene D.
    THERAPEUTIC DRUG MONITORING, 2017, 39 (06) : 596 - 603
  • [45] Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study
    Del Romero, Jorge
    Castilla, Jesus
    Hernando, Victoria
    Rodriguez, Carmen
    Garcia, Soledad
    BMJ-BRITISH MEDICAL JOURNAL, 2010, 340 : 1179
  • [46] ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA < 500 000 Copies/mL
    Taiwo, Babafemi O.
    Zheng, Lu
    Stefanescu, Andrei
    Nyaku, Amesika
    Bezins, Baiba
    Wallis, Carole L.
    Godfrey, Catherine
    Sax, Paul E.
    Acosta, Edward
    Haas, David
    Smith, Kimberly Y.
    Sha, Beverly
    Van Dam, Cornelius
    Gulic, Roy M.
    CLINICAL INFECTIOUS DISEASES, 2018, 66 (11) : 1689 - 1697
  • [47] Characteristics of HIV-1 Serodiscordant Couples Enrolled in a Clinical Trial of Antiretroviral Pre-Exposure Prophylaxis for HIV-1 Prevention
    Mujugira, Andrew
    Baeten, Jared M.
    Donnell, Deborah
    Ndase, Patrick
    Mugo, Nelly R.
    Barnes, Linda
    Campbell, James D.
    Wangisi, Jonathan
    Tappero, Jordan W.
    Bukusi, Elizabeth
    Cohen, Craig R.
    Katabira, Elly
    Ronald, Allan
    Tumwesigye, Elioda
    Were, Edwin
    Fife, Kenneth H.
    Kiarie, James
    Farquhar, Carey
    John-Stewart, Grace
    Kidoguchi, Lara
    Panteleeff, Dana
    Krows, Meighan
    Shah, Heena
    Revall, Jennifer
    Morrison, Susan
    Ondrejcek, Lisa
    Ingram, Charlotte
    Coombs, Robert W.
    Lingappa, Jairam R.
    Celum, Connie
    PLOS ONE, 2011, 6 (10):
  • [48] Obstacles to successful antiretroviral treatment of HIV-1 infection:: problems & perspectives
    Potter, SJ
    Chew, CB
    Steain, M
    Dwyer, DE
    Saksena, NK
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2004, 119 (06) : 217 - 237
  • [49] Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
    Mu, Wenli
    Zhen, Anjie
    Carrillo, Mayra A.
    Rezek, Valerie
    Martin, Heather
    Lizarraga, Miguel
    Kitchen, Scott
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2022, (188):
  • [50] Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations
    Skrabal, K
    Trouplin, V
    Labrosse, B
    Obry, V
    Damond, F
    Hance, AJ
    Clavel, F
    Mammano, F
    AIDS, 2003, 17 (06) : 809 - 814